SecBot SecBot
EFFECT ·Filed Jul 16, 2026

ESPR

Esperion Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago SEC9999999995-26-002302
Actionable Insight ▼ Bearish

The dual shelf effectiveness removes a procedural barrier to raising capital. With weak analyst sentiment and minimal institutional support, the risk of a dilutive offering is elevated. Traders should watch for a prospectus supplement or 424B filing that would signal an actual offering, that event would likely pressure the stock.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics received SEC effectiveness on two shelf registration statements (File Nos. 333-201198 and 333-197125) on July 15, 2026. Both are now effective, giving the company the ability to offer and sell securities at any time. This creates a potential dilution overhang for common shareholders, as the company can tap the market without further notice.

Key Facts

  • Two shelf registration statements (333-201198 and 333-197125) declared effective by the SEC on July 15, 2026.
  • Both are 1933 Act filings, enabling Esperion to offer and sell securities (common stock, preferred stock, warrants, etc.) at its discretion.
  • No specific offering size, pricing, or terms were disclosed in the effectiveness notices.
  • The company has a market cap of approximately $819M and is covered by 0 Strong Buy ratings (0% bullish analyst consensus).
  • Top institutional holder Wasatch Advisors holds only $6M, and recent 13F activity shows a near-exit move.

Financial Impact

Potential dilution of unknown size, shelf registrations allow for offerings up to undisclosed amounts. Any future offering could dilute existing common shareholders.

dilutionshare countequity value

Risk Factors

  • Potential dilutive equity offering at any time without prior notice.
  • Weak analyst consensus (0% bullish) and low institutional conviction (Wasatch near-exit) suggest limited demand for the stock.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (ESPR), Batch item 19999999995-26-002302
Document: 9999999995-26-002302-index.html9999999995-26-002301
Document: 9999999995-26-002302.txt9999999995-26-002302
EFFECT Filing (ESPR), Batch item 49999999995-26-002301
Document: 9999999995-26-002301-index.html9999999995-26-002302
Document: 9999999995-26-002301.txt9999999995-26-002302

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Viewing Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 16, 2026